Insilico Deepens ASKA Partnership to Expand AI-Driven Women’s Health Pipeline

New updates have been reported about Insilico Medicine.

Insilico Medicine (3696.HK) has entered a new strategic research collaboration with Japan’s ASKA Pharmaceutical to use its AI target discovery platform PandaOmics to uncover novel drug targets for difficult gynecological diseases, including endometriosis, uterine fibroids, and adenomyosis. The deal broadens an existing software relationship and is intended to generate high-value, clinically translatable targets that can feed both partners’ pipelines in a segment with large unmet need and substantial global prevalence.

Under the agreement, Insilico’s Target Discovery team, led by Hong Kong site head Dr. Frank Pun, will apply PandaOmics and its new Target Identification Pro (TargetPro) framework to build disease-specific models and nominate context-dependent targets with higher probability of advancing to the clinic. ASKA will be responsible for experimentally validating the AI-prioritized targets and progressing the most promising candidates, reflecting its strategy to embed AI across R&D and accelerate women’s health innovation. Insilico highlights prior preclinical validation of AI-derived endometriosis targets as proof of concept, positioning this collaboration as a way to convert its Hong Kong–listed AI platform into tangible partnering revenue and optional future milestones in a large, chronic therapeutic market.